An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma
暂无分享,去创建一个
B. Neyns | S. Aspeslagh | A. Van Binst | H. Everaert | G. Awada | J. Schwarze | S. D. Keukeleire | L. Cras
[1] D. Pisetsky,et al. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors , 2019, Rheumatology.
[2] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[3] H. Tran,et al. Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma , 2019, Case Reports in Oncology.
[4] L. Hakim-Meibodi,et al. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab , 2019, Melanoma research.
[5] D. Schadendorf,et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[6] G. Prévot,et al. Granulomatose sarcoïdosique survenant sous inhibiteurs de point de contrôle immunitaire , 2018, Revue des Maladies Respiratoires.
[7] K. Syrigos,et al. Sarcoidosis‐Like Reactions Induced by Checkpoint Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] L. Ny,et al. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. , 2018, The Lancet. Oncology.
[9] C. Balleyguier,et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. , 2018, European journal of cancer.
[10] D. Schadendorf,et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.
[11] R. Braun,et al. Sarcoid-like reactions in patients receiving modern melanoma treatment , 2018, Melanoma research.
[12] B. Firwana,et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[13] P. Ascierto,et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.
[14] K. Shannon,et al. Immunotherapy‐induced sarcoidosis in patients with melanoma treated with PD‐1 checkpoint inhibitors: Case series and immunophenotypic analysis , 2017, International journal of rheumatic diseases.
[15] Paul R. Kunk,et al. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature , 2016, Journal of Immunotherapy for Cancer.
[16] C. Querfeld,et al. Pembrolizumab-associated sarcoidosis , 2016, JAAD case reports.
[17] I. Svane,et al. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab , 2014, Oncoimmunology.
[18] A. Prasse,et al. Sarcoidosis , 2014, The Lancet.
[19] B. Neyns,et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. , 2012, Anticancer research.
[20] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.